The latest updates on drug candidate KM-819.

FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of Company’s Parkinson’s Disease Treatment with Approval from U.S. Food and Drug AdministrationRead Now >

Tuesday, November 23, 2021 / BioSpace

FDA Approval Sought to Begin Phase 2 Trial of KM-819Read Now >

Wednesday, November 17, 2021 / Parkinson's News Today